Samchundang Pharm Submits European Clinical Trial Application for Oral Insulin
Samchundang Pharm announced on the 19th that it has submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMEA) for its oral insulin candidate.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Fed Turns Hawkish in a Month, Hints at Possibility of "Additional Policy Firming"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The purpose of the clinical trial is to evaluate and compare the pharmacokinetic and pharmacodynamic properties of the oral insulin candidate (SCD0503) with those of subcutaneous insulin under normal glucose clamp conditions in patients with type 1 diabetes. The clinical trial period is expected to be within approximately nine months from the date of approval.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
